Latest Utilities News

Ironbark Balanced Income Limited reported a solid half-year profit increase of 14.6%, driven by strong portfolio returns and a strategic shift to quarterly dividends. The company declared a fully franked interim dividend of 1.3 cents per share payable in March 2026.

Etherstack plc reported a robust FY2025 financial rebound with revenue soaring 70% to US$10.1 million, driven by major US project deliveries and a 62% rise in recurring support revenues. The company also turned EBITDA positive and secured key long-term contracts, setting the stage for strong growth in 2026.

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.

Synertec Corporation has won operational technology contracts exceeding $1 million with Sydney Water, marking a significant step in its national expansion within Australia's water infrastructure sector.

FortifAI Limited has raised $5 million through a strategic placement led by a major Australian institutional fund manager, reinforcing its balance sheet and accelerating its AI development and commercialisation plans.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Inghams Group reports flat revenue but a sharp 42% drop in EBITDA for the first half of FY26, revising full-year earnings guidance lower amid ongoing cost inflation and operational challenges.

Zip Co has delivered a standout half-year performance with record cash earnings and upgraded FY26 guidance, driven by strong US market momentum and innovative product launches.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Atturra Limited confirms its FY26 revenue and EBITDA guidance, acknowledging a contract termination impact in H1 but optimistic about a stronger second half.